NCT04349241View on ClinicalTrials.gov

Efficacy and Safety of Favipiravir in Management of COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 18, 2020

Primary Completion Date

June 1, 2020

Study Completion Date

June 20, 2020

Conditions
Coronavirus Disease (COVID-19)
Interventions
DRUG

favipiravir

pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor

DRUG

Standard of care therapy

oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10

Trial Locations (1)

11566

Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT04349241 - Efficacy and Safety of Favipiravir in Management of COVID-19 | Biotech Hunter | Biotech Hunter